---
title: "CGNNT: Subsidiary CGN Medical Technology plans to increase capital by 500 million yuan from the company's controlling shareholder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243698640.md"
description: "CGNNT announced that its controlling shareholder, China General Nuclear Power Technology Application Co., Ltd., plans to increase its investment by RMB 500 million to its wholly-owned subsidiary, CGN Medical Technology, for proton medical research and development projects and business development. After the capital increase, the controlling shareholder will hold 44.13% of the equity in the medical technology company, while the company will hold 55.87% of the equity, and the medical technology company will still be a controlled subsidiary. This move demonstrates the controlling shareholder's support for the listed company"
datetime: "2025-06-09T11:33:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243698640.md)
  - [en](https://longbridge.com/en/news/243698640.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243698640.md)
---

# CGNNT: Subsidiary CGN Medical Technology plans to increase capital by 500 million yuan from the company's controlling shareholder

According to the announcement from CGNNT (000881.SZ), the company's controlling shareholder, CGN Nuclear Technology Application Co., Ltd. (hereinafter referred to as "Nuclear Technology Company"), intends to increase its capital by RMB 500 million in cash to the company's wholly-owned subsidiary, CGN Medical Technology (Mianyang) Co., Ltd. (hereinafter referred to as "Medical Technology Company"), for the development of proton medical research projects and future business development. After the capital increase, the Nuclear Technology Company will hold 44.13% of the shares in the Medical Technology Company, while the company will hold 55.87% of the shares, and the Medical Technology Company will still be a controlling subsidiary of the company.

The announcement stated that the company fully introduced the multi-room proton therapy technology from Belgium's IBA in 2020, obtaining exclusive rights for the development, manufacturing, sales, installation, operation, and maintenance of this technology and products in mainland China. The capital increase will be used for the Medical Technology Company's proton medical research projects and future business development, reflecting the controlling shareholder's support for the listed company

### Related Stocks

- [000881.CN](https://longbridge.com/en/quote/000881.CN.md)
- [01164.HK](https://longbridge.com/en/quote/01164.HK.md)

## Related News & Research

- [Exploring Three Undiscovered Gems in the Middle East Market](https://longbridge.com/en/news/286881831.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [15:37 ETMuse Communications Celebrates 10 Years of Award-Winning Legal Marketing and Public Relations](https://longbridge.com/en/news/286811115.md)
- [Nuclear reactor developer Deep Fission eyes $1.66 billion valuation in US IPO](https://longbridge.com/en/news/287062992.md)
- [Kalshi Becomes Target Of Prediction Market 'Watchdog' Ad Campaign: They Have 'Lot Of Explaining To Do'](https://longbridge.com/en/news/287164059.md)